Healthtech companies will find that the conference offers them an opportunity, through the demonstration sessions, to show their latest advances to an important audience. Sessions on available funding mechanisms and how they might be applied for will also be of particular interest. An understanding of local clinical concerns will be provided by clinical experts with experience of the Chinese healthcare   system.

Academics will find a positive atmosphere in which new opportunities for collaboration may be identified. Sessions on spin--‐out activity and tech transfer will be of interest to those academics at the interface with healthcare practice, for whom getting ideas out of the lab and into the Chinese healthcare system is a priority.

Governmental representatives from both Western and Chinese departments will find the informative coverage of “next generation” technologies useful, in helping to identify future policy requirements and in understanding advances being made in company and academic research labs. 

Charities will find partners with whom new clinical studies may be initiated, and new technologies that may address unmet needs within their charitable remit. Engagement with funding agencies will also be useful.

Clinicans and healthcare workers will likewise find the informative nature of the conference to be professionally useful, and may inform purchasing decisions for hospitals and clinics. The move to evidence--‐based medicine is a key contributor to the manner in which healthtech products and services are developed and such information will be available through engagement with industry and academia.

Tech transfer entities will be able to form new partnerships with SMEs (small and  medium sized enterprises), and with university spin‐out companies. An improved understanding of the state of modern healthtech systems will be a particularly useful outcome.